JPS6490133A - Pharmaceutical preparation for oral administration - Google Patents

Pharmaceutical preparation for oral administration

Info

Publication number
JPS6490133A
JPS6490133A JP62245592A JP24559287A JPS6490133A JP S6490133 A JPS6490133 A JP S6490133A JP 62245592 A JP62245592 A JP 62245592A JP 24559287 A JP24559287 A JP 24559287A JP S6490133 A JPS6490133 A JP S6490133A
Authority
JP
Japan
Prior art keywords
active component
histidylhistidine
cyclo
bis
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62245592A
Other languages
Japanese (ja)
Inventor
Toshizane Kanbe
Hironobu Ishiyama
Yoshimasa Nakano
Nobutaka Fujisawa
Kiyohiko Magata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP62245592A priority Critical patent/JPS6490133A/en
Publication of JPS6490133A publication Critical patent/JPS6490133A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To provide the titled preparation containing bis[cyclo(histidylhistidine)] copper salt complex as an active component, effective in removing active oxygen and preventing the formation of lipid peroxide in the living body, exhibiting prolonged effect by oral administration and useful as a remedy for hepatic diseases, etc., having low side effect. CONSTITUTION:The objective preparation contains a bis[cyclo(histidylhistidine)] copper salt complex as an active component. The above active component is formed in the form of tablet, granule, etc., together with a conventional drug preparation carrier. The content of the active component compound is usually about 1-70wt.%, preferably about 1-30wt.% in the whole composition. The amount of the active component compound in the administration unit is preferably about 0.1-100mg. It may be administered in the form of parenteral drug e.g. injection according to the symptom. An example of the above active component compound is bis[cyclo(histidylhistidine)] copper (II) (ClO4<->)2.
JP62245592A 1987-09-29 1987-09-29 Pharmaceutical preparation for oral administration Pending JPS6490133A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62245592A JPS6490133A (en) 1987-09-29 1987-09-29 Pharmaceutical preparation for oral administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62245592A JPS6490133A (en) 1987-09-29 1987-09-29 Pharmaceutical preparation for oral administration

Publications (1)

Publication Number Publication Date
JPS6490133A true JPS6490133A (en) 1989-04-06

Family

ID=17136021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62245592A Pending JPS6490133A (en) 1987-09-29 1987-09-29 Pharmaceutical preparation for oral administration

Country Status (1)

Country Link
JP (1) JPS6490133A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2806911A1 (en) * 2000-03-28 2001-10-05 Univ Rene Descartes USE OF SOD MIMETICS IN THE TREATMENT OF HEPATOCELLULAR INSUFFICIENCY

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2806911A1 (en) * 2000-03-28 2001-10-05 Univ Rene Descartes USE OF SOD MIMETICS IN THE TREATMENT OF HEPATOCELLULAR INSUFFICIENCY
WO2001072327A3 (en) * 2000-03-28 2002-03-28 Univ Paris Descartes Use of analogues of superoxide dismutase for treating hepatocellular insufficiencies

Similar Documents

Publication Publication Date Title
EP0234733B1 (en) Pharmaceutical compositions
US5569670A (en) Combination medications containing alpha-lipoic acid and related
EP1283054A4 (en) Drugs for complications of diabetes and neuropathy and utilization thereof
CA2208047A1 (en) Increasing creatine and glycogen concentration in muscle
KR920000324A (en) Essential Fatty Acid Treatment
CA2297834C (en) Chromium/biotin treatment of type ii diabetes
HUT67661A (en) New pyrazine derivatives, their preparation and pharmaceutical compositions containing them
CA2072366A1 (en) Carboxylic acid-metal ion-acid complexes
KR970025615A (en) Cancer metastasis inhibitor
JPS63270626A (en) Antiulcer agent
AU1879597A (en) Tetraether lipids and liposomes containing said lipids, and use of the same
CA2016470C (en) Pharmaceutical preparation and method of treatment for liver dysfunction
WO1991018606A3 (en) Orally active nonaddicting analgesics
JPS6490133A (en) Pharmaceutical preparation for oral administration
KR920702225A (en) Pharmaceutical composition
JPS5350316A (en) Drug composition for oral administration
JPS5551019A (en) Drug containing alllee or 133zz7*88dehydroo retine acid and manufacture thereof
CA1197782A (en) Pharmaceutical and dietary composition
JPH04244022A (en) Drug for suppressing thyroid-stimulating hormone and curing struma
JPS56115715A (en) Physiologically active agent containing (3- dimethylcarbam-oxyphenyl) trimethyl ammonium derivative
KR900700102A (en) Long-lasting composition of propaphenone and quinidine for the treatment of heart disease
KR910006270A (en) Pharmacologically active compound preparations and uses
JPS646214A (en) Remedy for ulcerative colonopathy
SU606242A1 (en) &#34;dimotziphon&#34; anti-leprose preparation
JPS63192717A (en) Drug for hepatic disease